Cargando…
Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial
BACKGROUND: Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis th...
Autores principales: | Gomez-Manjarres, Diana C., Axell-House, Dierdre B., Patel, Divya C., Odackal, John, Yu, Victor, Burdick, Marie D., Mehrad, Borna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243828/ https://www.ncbi.nlm.nih.gov/pubmed/36853800 http://dx.doi.org/10.1172/jci.insight.166901 |
Ejemplares similares
-
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
por: Odackal, John, et al.
Publicado: (2020) -
Circulating fibrocytes traffic to the lung in murine acute lung injury and predict outcomes in human acute respiratory distress syndrome: a pilot study
por: Lin, Christine M., et al.
Publicado: (2020) -
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease
por: Mehrad, Borna, et al.
Publicado: (2012) -
The role of fibrocytes in fibrotic diseases of the lungs and heart
por: Keeley, Ellen C, et al.
Publicado: (2011) -
The Role of Fibrocytes in Sickle Cell Lung Disease
por: Field, Joshua J., et al.
Publicado: (2012)